T-knife
Berlin
About T-knife
T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCR╬▒╬▓ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $197.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2021)
- Website: t-knife.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/t-knife-121411 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.